BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38639952)

  • 21. The impact of core length on prostate cancer diagnosis during a standard 14-core prostate biopsy scheme.
    Dell'Atti L; Ippolito C
    Urologia; 2016 Nov; 83(4):186-189. PubMed ID: 27716886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores.
    Seisen T; Roudot-Thoraval F; Bosset PO; Beaugerie A; Allory Y; Vordos D; Abbou CC; De La Taille A; Salomon L
    World J Urol; 2015 Jun; 33(6):787-92. PubMed ID: 24985552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
    JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer.
    Dickinson L; Ahmed HU; Hindley RG; McCartan N; Freeman A; Allen C; Emberton M; Kirkham AP
    Urol Oncol; 2017 Jan; 35(1):30.e9-30.e15. PubMed ID: 27663393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of the transition zone index for identification of prostate cancer in Chinese men with intermediate PSA levels.
    Qi TY; Chen YQ; Jiang J; Zhu YK; Yao XH; Wang XJ
    Int Urol Nephrol; 2012 Jun; 44(3):807-15. PubMed ID: 22311386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate.
    Stone NN; Crawford ED; Skouteris VM; Arangua P; Metsinis PM; Lucia MS; La Rosa FG; Werahera PN
    J Urol; 2019 Aug; 202(2):264-271. PubMed ID: 30835628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
    Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
    BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk.
    Miah S; Hosking-Jervis F; Connor MJ; Eldred-Evans D; Shah TT; Arya M; Barber N; Bhardwa J; Bott S; Burke D; Doherty A; Foster C; Freeman A; Hindley R; Jameson C; Karim O; Laniado M; Montgomery B; Nigam R; Punwani S; Sinclair A; Winkler M; Allen C; Ahmed HU
    Eur Urol Oncol; 2020 Jun; 3(3):262-269. PubMed ID: 31411968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The eternal enigma in prostatic biopsy access route.
    Fabiani A; Principi E; Filosa A; Servi L
    Arch Ital Urol Androl; 2017 Oct; 89(3):245-246. PubMed ID: 28969413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
    Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
    Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen nomogram to predict advanced prostate cancer using area under the receiver operating characteristic curve boosting.
    Hashimoto T; Komori O; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Shishido T; Namiki K; Ohno Y
    Urol Oncol; 2022 Apr; 40(4):162.e9-162.e16. PubMed ID: 35065881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution.
    Nan LB; Yin XT; Gao JP
    Med Sci Monit; 2019 Nov; 25():8345-8351. PubMed ID: 31691648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism underlying the negative effect of prostate volume on the outcome of extensive transperineal ultrasound-guided template prostate biopsy.
    Demura T; Takada T; Shimoda N; Hioka T; Iwaguchi Y; Ichihara S; Gotoda H
    Cancer Med; 2018 Feb; 7(2):336-343. PubMed ID: 29341453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
    Bulbul MA; Khauli RB; Nasr R; Hemady K; Wazzan W
    J Med Liban; 2000; 48(2):59-62. PubMed ID: 11028151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
    Lee J; Yang SW; Jin L; Lee CL; Lee JY; Shin JH; Lim JS; Song KH
    BMC Cancer; 2021 Apr; 21(1):472. PubMed ID: 33910525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?
    Pepe P; Fraggetta F; Galia A; Skonieczny G; Aragona F
    Int Braz J Urol; 2012; 38(4):489-95. PubMed ID: 22951161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies.
    Gershman B; Zietman AL; Feldman AS; McDougal WS
    Urol Oncol; 2013 Oct; 31(7):1093-7. PubMed ID: 22305626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.